Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Misc Car-T Activity

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron Jul 12, 2023 1:28pm

120 Views

Post# 35537758

RE:RE:Misc Car-T Activity

@Noteable. In the recent CAR T poster that I cannot find, I think they did not use the boost. So if this cofirmation study used a boost that is very interesting. I have not seen any of this in writing, but if it is pela, WOW.

<< Previous

Bullboard Posts

Next >>

Mullen Group: Navigates market challenges towards success